3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Venous Thromboembolism
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
23
Nivolumab
20
atezolizumab
10
Specimen Handling
8
Ipilimumab
8
Cyclophosphamide
8
cabozantinib
6
Magnetic Resonance Spectroscopy
6
fludarabine
5
Sorafenib
5
sargramostim
4
Trastuzumab
4
Sunitinib
4
Bevacizumab
4
lenvatinib
3
enzalutamide
3
durvalumab
3
avelumab
3
X-Rays
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
spartalizumab
2
relatlimab
2
regorafenib
2
palbociclib
2
epacadostat
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Rivaroxaban
×
Genitourinary
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled